Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

American Civil War plant medicines inhibit growth, biofilm formation, and quorum sensing by multidrug-resistant bacteria.

Dettweiler M, Lyles JT, Nelson K, Dale B, Reddinger RM, Zurawski DV, Quave CL.

Sci Rep. 2019 May 22;9(1):7692. doi: 10.1038/s41598-019-44242-y.

2.

Skin and Soft Tissue Models for Acinetobacter baumannii Infection.

Zurawski DV, Banerjee J, Alamneh YA, Shearer JP, Demons ST.

Methods Mol Biol. 2019;1946:271-287. doi: 10.1007/978-1-4939-9118-1_25.

PMID:
30798563
3.

A Porcine Wound Model of Acinetobacter baumannii Infection.

Zurawski DV, Black CC, Alamneh YA, Biggemann L, Banerjee J, Thompson MG, Wise MC, Honnold CL, Kim RK, Paranavitana C, Shearer JP, Tyner SD, Demons ST.

Adv Wound Care (New Rochelle). 2019 Jan 1;8(1):14-27. doi: 10.1089/wound.2018.0786. Epub 2019 Jan 5.

4.

Extracellular polymeric substance (EPS)-degrading enzymes reduce staphylococcal surface attachment and biocide resistance on pig skin in vivo.

Kaplan JB, Mlynek KD, Hettiarachchi H, Alamneh YA, Biggemann L, Zurawski DV, Black CC, Bane CE, Kim RK, Granick MS.

PLoS One. 2018 Oct 10;13(10):e0205526. doi: 10.1371/journal.pone.0205526. eCollection 2018.

5.

Narrow-Spectrum Antibacterial Agents.

Melander RJ, Zurawski DV, Melander C.

Medchemcomm. 2018;9:12-21. doi: 10.1039/C7MD00528H. Epub 2017 Nov 6.

6.

SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii.

Zurawski DV, Reinhart AA, Alamneh YA, Pucci MJ, Si Y, Abu-Taleb R, Shearer JP, Demons ST, Tyner SD, Lister T.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01239-17. doi: 10.1128/AAC.01239-17. Print 2017 Dec.

7.

The Galleria mellonella larvae as an in vivo model for evaluation of Shigella virulence.

Barnoy S, Gancz H, Zhu Y, Honnold CL, Zurawski DV, Venkatesan MM.

Gut Microbes. 2017 Jul 4;8(4):335-350. doi: 10.1080/19490976.2017.1293225. Epub 2017 Feb 13.

8.

1,2,4-Triazolidine-3-thiones as Narrow Spectrum Antibiotics against Multidrug-Resistant Acinetobacter baumannii.

Huggins WM, Minrovic BM, Corey BW, Jacobs AC, Melander RJ, Sommer RD, Zurawski DV, Melander C.

ACS Med Chem Lett. 2016 Nov 12;8(1):27-31. doi: 10.1021/acsmedchemlett.6b00296. eCollection 2017 Jan 12.

9.

In Vivo Fitness Adaptations of Colistin-Resistant Acinetobacter baumannii Isolates to Oxidative Stress.

Jones CL, Singh SS, Alamneh Y, Casella LG, Ernst RK, Lesho EP, Waterman PE, Zurawski DV.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e00598-16. doi: 10.1128/AAC.00598-16. Print 2017 Mar.

10.

1,2,4-Triazolidine-3-thiones Have Specific Activity against Acinetobacter baumannii among Common Nosocomial Pathogens.

Corey BW, Thompson MG, Hittle LE, Jacobs AC, Asafo-Adjei EA, Huggins WM, Melander RJ, Melander C, Ernst RK, Zurawski DV.

ACS Infect Dis. 2017 Jan 13;3(1):62-71. doi: 10.1021/acsinfecdis.6b00133. Epub 2016 Nov 3.

11.

Copper Resistance of the Emerging Pathogen Acinetobacter baumannii.

Williams CL, Neu HM, Gilbreath JJ, Michel SL, Zurawski DV, Merrell DS.

Appl Environ Microbiol. 2016 Sep 30;82(20):6174-6188. Print 2016 Oct 15.

12.

Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, Zurawski DV, Teneza-Mora NC, Biswas B, Hall ER.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5806-16. doi: 10.1128/AAC.02877-15. Print 2016 Oct.

13.

The First Cut Is the Deepest: The History and Development of Safe Treatments for Wound Healing and Tissue Repair.

Hobson DW, Schuh JC, Zurawski DV, Wang J, Arbabi S, McVean M, Funk KA.

Int J Toxicol. 2016 Sep;35(5):491-8. doi: 10.1177/1091581816656804. Epub 2016 Jul 8.

PMID:
27402775
14.

Evaluation of Parameters for High Efficiency Transformation of Acinetobacter baumannii.

Yildirim S, Thompson MG, Jacobs AC, Zurawski DV, Kirkup BC.

Sci Rep. 2016 Feb 25;6:22110. doi: 10.1038/srep22110.

15.

Joint Transcriptional Control of Virulence and Resistance to Antibiotic and Environmental Stress in Acinetobacter baumannii.

Gebhardt MJ, Gallagher LA, Jacobson RK, Usacheva EA, Peterson LR, Zurawski DV, Shuman HA.

MBio. 2015 Nov 10;6(6):e01660-15. doi: 10.1128/mBio.01660-15.

16.

Evaluation of Gallium Citrate Formulations against a Multidrug-Resistant Strain of Klebsiella pneumoniae in a Murine Wound Model of Infection.

Thompson MG, Truong-Le V, Alamneh YA, Black CC, Anderl J, Honnold CL, Pavlicek RL, Abu-Taleb R, Wise MC, Hall ER, Wagar EJ, Patzer E, Zurawski DV.

Antimicrob Agents Chemother. 2015 Oct;59(10):6484-93. doi: 10.1128/AAC.00882-15. Epub 2015 Aug 3.

17.

Resources for Genetic and Genomic Analysis of Emerging Pathogen Acinetobacter baumannii.

Gallagher LA, Ramage E, Weiss EJ, Radey M, Hayden HS, Held KG, Huse HK, Zurawski DV, Brittnacher MJ, Manoil C.

J Bacteriol. 2015 Jun 15;197(12):2027-35. doi: 10.1128/JB.00131-15. Epub 2015 Apr 6.

18.

Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence.

Jones CL, Clancy M, Honnold C, Singh S, Snesrud E, Onmus-Leone F, McGann P, Ong AC, Kwak Y, Waterman P, Zurawski DV, Clifford RJ, Lesho E.

Clin Infect Dis. 2015 Jul 15;61(2):145-54. doi: 10.1093/cid/civ225. Epub 2015 Mar 29.

PMID:
25824815
19.

Draft Genome Sequences of Klebsiella pneumoniae Clinical Type Strain ATCC 13883 and Three Multidrug-Resistant Clinical Isolates.

Arivett BA, Ream DC, Fiester SE, Mende K, Murray CK, Thompson MG, Kanduru S, Summers AM, Roth AL, Zurawski DV, Actis LA.

Genome Announc. 2015 Jan 15;3(1). pii: e01385-14. doi: 10.1128/genomeA.01385-14.

20.

Genetic Manipulation of Acinetobacter baumannii.

Jacobs AC, Thompson MG, Gebhardt M, Corey BW, Yildirim S, Shuman HA, Zurawski DV.

Curr Protoc Microbiol. 2014 Nov 3;35:6G.2.1-11. doi: 10.1002/9780471729259.mc06g02s35.

PMID:
25367274
21.

Laboratory Maintenance of Acinetobacter baumannii.

Jacobs AC, Zurawski DV.

Curr Protoc Microbiol. 2014 Nov 3;35:6G.1.1-6. doi: 10.1002/9780471729259.mc06g01s35.

PMID:
25367273
22.

Staphylococcus aureus hyaluronidase is a CodY-regulated virulence factor.

Ibberson CB, Jones CL, Singh S, Wise MC, Hart ME, Zurawski DV, Horswill AR.

Infect Immun. 2014 Oct;82(10):4253-64. doi: 10.1128/IAI.01710-14. Epub 2014 Jul 28.

23.

AB5075, a Highly Virulent Isolate of Acinetobacter baumannii, as a Model Strain for the Evaluation of Pathogenesis and Antimicrobial Treatments.

Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, Gancz HY, Corey BW, Moon JK, Si Y, Owen MT, Hallock JD, Kwak YI, Summers A, Li CZ, Rasko DA, Penwell WF, Honnold CL, Wise MC, Waterman PE, Lesho EP, Stewart RL, Actis LA, Palys TJ, Craft DW, Zurawski DV.

MBio. 2014 May 27;5(3):e01076-14. doi: 10.1128/mBio.01076-14.

24.

Validation of a novel murine wound model of Acinetobacter baumannii infection.

Thompson MG, Black CC, Pavlicek RL, Honnold CL, Wise MC, Alamneh YA, Moon JK, Kessler JL, Si Y, Williams R, Yildirim S, Kirkup BC Jr, Green RK, Hall ER, Palys TJ, Zurawski DV.

Antimicrob Agents Chemother. 2014;58(3):1332-42. doi: 10.1128/AAC.01944-13. Epub 2013 Dec 16.

25.

Antimicrobial resistance determinants in Acinetobacter baumannii isolates taken from military treatment facilities.

Taitt CR, Leski TA, Stockelman MG, Craft DW, Zurawski DV, Kirkup BC, Vora GJ.

Antimicrob Agents Chemother. 2014;58(2):767-81. doi: 10.1128/AAC.01897-13. Epub 2013 Nov 18.

26.

Small molecule downregulation of PmrAB reverses lipid A modification and breaks colistin resistance.

Harris TL, Worthington RJ, Hittle LE, Zurawski DV, Ernst RK, Melander C.

ACS Chem Biol. 2014 Jan 17;9(1):122-7. doi: 10.1021/cb400490k. Epub 2013 Oct 28.

PMID:
24131198
27.

Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii.

Pelletier MR, Casella LG, Jones JW, Adams MD, Zurawski DV, Hazlett KR, Doi Y, Ernst RK.

Antimicrob Agents Chemother. 2013 Oct;57(10):4831-40. doi: 10.1128/AAC.00865-13. Epub 2013 Jul 22.

28.

Reply to "The Dual personality of iron chelators: growth inhibitors or promoters?".

Zurawski DV, Jacobs AC, Thompson MG, Palys TJ.

Antimicrob Agents Chemother. 2013 May;57(5):2434. doi: 10.1128/AAC.00134-13. No abstract available.

29.

Detection of bacterial 16S rRNA and identification of four clinically important bacteria by real-time PCR.

Clifford RJ, Milillo M, Prestwood J, Quintero R, Zurawski DV, Kwak YI, Waterman PE, Lesho EP, Mc Gann P.

PLoS One. 2012;7(11):e48558. doi: 10.1371/journal.pone.0048558. Epub 2012 Nov 6.

30.

Antibacterial activities of iron chelators against common nosocomial pathogens.

Thompson MG, Corey BW, Si Y, Craft DW, Zurawski DV.

Antimicrob Agents Chemother. 2012 Oct;56(10):5419-21. doi: 10.1128/AAC.01197-12. Epub 2012 Jul 30.

31.

Extracellular stress and lipopolysaccharide modulate Acinetobacter baumannii surface-associated motility.

McQueary CN, Kirkup BC, Si Y, Barlow M, Actis LA, Craft DW, Zurawski DV.

J Microbiol. 2012 Jun;50(3):434-43. doi: 10.1007/s12275-012-1555-1. Epub 2012 Jun 30.

PMID:
22752907
32.

Traumatic wound microbiome workshop.

Kirkup BC Jr, Craft DW, Palys T, Black C, Heitkamp R, Li C, Lu Y, Matlock N, McQueary C, Michels A, Peck G, Si Y, Summers AM, Thompson M, Zurawski DV.

Microb Ecol. 2012 Oct;64(3):837-50. Epub 2012 May 24.

PMID:
22622764
33.

Genome sequences of four divergent multidrug-resistant Acinetobacter baumannii strains isolated from patients with sepsis or osteomyelitis.

Zurawski DV, Thompson MG, McQueary CN, Matalka MN, Sahl JW, Craft DW, Rasko DA.

J Bacteriol. 2012 Mar;194(6):1619-20. doi: 10.1128/JB.06749-11.

34.

Shigella flexneri type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein.

Zurawski DV, Mumy KL, Faherty CS, McCormick BA, Maurelli AT.

Mol Microbiol. 2009 Jan;71(2):350-68. doi: 10.1111/j.1365-2958.2008.06524.x. Epub 2008 Nov 14.

35.
36.

OspF and OspC1 are Shigella flexneri type III secretion system effectors that are required for postinvasion aspects of virulence.

Zurawski DV, Mitsuhata C, Mumy KL, McCormick BA, Maurelli AT.

Infect Immun. 2006 Oct;74(10):5964-76.

38.

Potential role of the EPEC translocated intimin receptor (Tir) in host apoptotic events.

Malish HR, Freeman NL, Zurawski DV, Chowrashi P, Ayoob JC, Sanger JW, Sanger JM.

Apoptosis. 2003 Mar;8(2):179-90.

PMID:
12766478
39.

Molecular characterization of the prototrophic Salmonella mutants defective for intraepithelial replication.

Suvarnapunya AE, Zurawski DV, Guy RL, Stein MA.

Infect Immun. 2003 Apr;71(4):2247-52.

40.
41.

Interaction of the enteropathogenic Escherichia coli protein, translocated intimin receptor (Tir), with focal adhesion proteins.

Freeman NL, Zurawski DV, Chowrashi P, Ayoob JC, Huang L, Mittal B, Sanger JM, Sanger JW.

Cell Motil Cytoskeleton. 2000 Dec;47(4):307-18.

PMID:
11093251
42.

Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine.

Pachuk CJ, Ciccarelli RB, Samuel M, Bayer ME, Troutman RD, Zurawski DV, Schauer JI, Higgins TJ, Weiner DB, Sosnoski DM, Zurawski VR, Satishchandran C.

Biochim Biophys Acta. 2000 Sep 29;1468(1-2):20-30.

Supplemental Content

Loading ...
Support Center